U

UroGen Pharma, Inc

Develops RTGel-based drug delivery for uro-oncology

Associate Director - Medical Affairs

Biology & BiotechConfirmed live in the last 24 hours
Full-timePrinceton, NJ, USA$160k - $180k /yr

About the Job

Requirements

  • Demonstrated experience in medical, legal, and regulatory review processes and/or Medical Information within the pharmaceutical or biotechnology industry.
  • A terminal degree (PhD, PharmD, or another doctorate) is required; an equivalent combination of education and applicable job experience may be considered.
  • Excellent oral and written communication skills, including presentation skills.
  • Excellent interpersonal skills, with the ability to understand and respond to multiple internal and external stakeholder needs and manage conflict constructively.
  • Demonstrated clinical and scientific expertise, including experience working with clinical trials.
  • Ability to work collaboratively with Medical Affairs and cross-functional teams.
  • Demonstrated leadership and teamwork with peers and internal and external stakeholders, fostering alignment around a shared vision or strategy.
  • Ability to travel for internal meetings and congresses.

Responsibilities

  • Lead day-to-day coordination of PARC and MRC submissions and reviews for Medical Affairs materials, ensuring alignment with applicable policies, procedures, and review timelines.
  • Serve as the primary Medical Affairs point of contact for PARC/MRC operations and partner with Legal, Regulatory, Compliance, Commercial, and other stakeholders to facilitate timely, high-quality reviews.
  • Conduct scientific and medical review of promotional and nonpromotional materials to support accuracy, balance, consistency with approved product information, and appropriate substantiation.
  • Manage submission readiness, including intake, reviewer assignment, meeting coordination, status tracking, documentation of decisions, and follow-up on required revisions and approvals.
  • Maintain PARC/MRC records, metrics, standard operating procedures, training materials, and process documentation; identify and implement opportunities to improve review quality and efficiency.
  • Provide guidance and training to Medical Affairs and cross-functional partners on PARC/MRC requirements, roles, workflows, and compliant scientific communication practices.
  • Support the development, approval, maintenance, and periodic review of Medical Information resources, including standard response letters, frequently asked questions, clinical dossiers, and other evidence-based materials.
  • Triage and respond to unsolicited medical information inquiries from healthcare professionals and other appropriate requestors with timely, accurate, balanced, and appropriately referenced information.
  • Support Medical Science Liaisons with literature searches, evidence evaluation, and development of scientifically rigorous responses to field medical requests; escalate complex or safety-related inquiries as appropriate.
  • Support onboarding, ongoing training, and scientific resource education for the Medical Science Liaison team and contribute to cross-functional training when appropriate.
  • Maintain Medical Information inquiry records, response documentation, literature resources, metrics, and relevant procedures in accordance with company requirements and applicable standards.
  • Partner with internal stakeholders and external service providers to monitor inquiry trends, identify content or training needs, and drive continuous improvement in Medical Information quality, consistency, and turnaround time.

Desired Qualifications

  • Urologic oncology and rare disease experience is a plus.

About the Company

UroGen Pharma, Inc

Develops RTGel-based drug delivery for uro-oncology

UroGen Pharma develops RTGel-based drug-delivery therapies for urothelial and specialty cancers, commercializing products like Jelmyto and ZUSDURI and advancing a pipeline that includes UGN-102, UGN-103, UGN-104, and UGN-301. Its RTGel platform is liquid at cool temperatures and gels at body temperature, allowing chemotherapy to stay at the treatment site longer for local, sustained exposure. The company differentiates itself by delivering established chemotherapy directly to the disease site to reduce systemic exposure and by building a multi-product portfolio focused on urothelial cancers. Its goal is to improve local treatment outcomes and grow a diversified, globally commercial portfolio through ongoing clinical development and partnerships.

Company size
201-500
Company stage
IPO
Headquarters
Princeton, NJ
Founded
2004

Recently Posted Jobs

Explore more opportunities at UroGen Pharma, Inc

See more jobs